Anthem Biosciences IPO Sees Massive 67x Subscription, GMP Soars, Allotment Steps Explained

Mumbai: The Initial Public Offering (IPO) of Anthem Biosciences Limited opened on July 14 and closed on July 16. The Rs 3,395 crore issue was a complete Offer for Sale (OFS) of 5.96 crore equity shares. Investors showed overwhelming interest, and the IPO was subscribed 67.42 times overall.

Retail category: 5.98 times

Non-Institutional Investors (NII): 44.70 times

Qualified Institutional Buyers (QIB): 192.80 times

This strong subscription highlights the massive demand among investors for this issue.

GMP Indicates Strong Listing Potential

According to market sources, the Grey Market Premium (GMP) for Anthem Biosciences IPO is currently around Rs 144, which is 25.2 percent higher than the issue price. The highest GMP recorded so far is Rs 156. This suggests that the stock may list at a significant premium on the exchanges.

How to Check Share Allotment Status

The share allotment will be finalized by the evening of July 17. Shares will be credited to successful investors’ demat accounts on July 18, and the listing date is July 21 on BSE and NSE.

To check IPO allotment status:

Visit the registrar's website: https://ris.kfintech.com/ipostatus/

Click on any one of the five available links.

Select Anthem Biosciences from the IPO dropdown.

Enter your PAN, application number, or demat details.

Fill the captcha and click submit to check your allotment status.

About the Company and Valuation

Founded in 2006, Anthem Biosciences is a leading Contract Research, Development, and Manufacturing Organization (CRDMO) that supports the entire drug development process. It operates in both small molecules and biologics, making it one of India’s few integrated CRDMOs.

Analysts at top brokerages like Anand Rathi and Canara Bank Securities recommended subscribing to the IPO, citing the company’s strong market presence, high margins, global clientele, and consistent profitability.

Although the IPO is valued at 71x P/E based on FY25 earnings, which seems slightly expensive compared to Syngene (51x) and Divi’s Labs (83x), analysts believe the premium is justified given the company's technical capabilities and scalability.

Disclaimer: The recommendations, opinions, and views mentioned are those of market experts and analysts. Investors should conduct their own research or consult financial advisors before making any investment decisions. Markets involve risks.